Exposure to electromagnetic fields does not modify neither the age of onset nor the disease progression in ALS patients.

Amyotrophic lateral sclerosis cross-sectional studies electromagnetic fields epidemiology prognosis

Journal

Amyotrophic lateral sclerosis & frontotemporal degeneration
ISSN: 2167-9223
Titre abrégé: Amyotroph Lateral Scler Frontotemporal Degener
Pays: England
ID NLM: 101587185

Informations de publication

Date de publication:
05 2023
Historique:
medline: 21 4 2023
pubmed: 12 11 2022
entrez: 11 11 2022
Statut: ppublish

Résumé

Being exposed to electromagnetic fields has been suggested to increase the risk of developing Amyotrophic Lateral Sclerosis (ALS). Here, we investigated the effect of exposure to electromagnetic fields on ALS onset age and progression rate (ΔALSFRS-r). A large cohort of ALS patients (n = 1098) was geolocalized at the time of their diagnosis. Concomitantly, data on the distribution of power lines and repeater antennas (extremely low frequency electromagnetic fields) during the same period were retrieved. Exposure to each repeater antenna was calculated as the sum of 1/(distance from each antenna)^2. Exposure to power lines was calculated assuming each patient's address as the center of several circles of variable radius (100, 250, 500, 1000, and 2000 m). For each radius, the exposure was calculated as the length of the power lines included in the circle. Finally, patients were divided into low- and high-exposed based on the median of the exposure and compared using the Mann-Whitney test. A regression model (one for each radius) was also performed. Neither the onset age nor the ΔALSFRS-r differed among patients' low- and high-exposed to electromagnetic fields. Similarly, we could not find any significant relationship using the regression models. Our findings suggest that electromagnetic fields do not modify the ALS phenotype or progression.

Identifiants

pubmed: 36367329
doi: 10.1080/21678421.2022.2142800
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

343-346

Auteurs

Rosario Vasta (R)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.

Stefano Callegaro (S)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.

Maurizio Grassano (M)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.

Antonio Canosa (A)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
Neurology 1, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
Institute of Cognitive Science and Technologies, National Research Council, Rome, Italy, and.

Sara Cabras (S)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.

Francesca Di Pede (F)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.

Enrico Matteoni (E)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.

Filippo De Mattei (F)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.

Federico Casale (F)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.

Paolina Salamone (P)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.

Letizia Mazzini (L)

ALS Center, Department of Neurology, Azienda Ospedaliero Universitaria Maggiore della Carità, and University of Piemonte Orientale, Novara, Italy.

Fabiola De Marchi (F)

ALS Center, Department of Neurology, Azienda Ospedaliero Universitaria Maggiore della Carità, and University of Piemonte Orientale, Novara, Italy.

Cristina Moglia (C)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
Neurology 1, AOU Città della Salute e della Scienza di Torino, Turin, Italy.

Andrea Calvo (A)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
Neurology 1, AOU Città della Salute e della Scienza di Torino, Turin, Italy.

Adriano Chiò (A)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
Neurology 1, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
Institute of Cognitive Science and Technologies, National Research Council, Rome, Italy, and.

Umberto Manera (U)

ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
Neurology 1, AOU Città della Salute e della Scienza di Torino, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH